With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs
Eur Heart J Cardiovasc Pharmacother
.
2017 Apr 1;3(2):75-76.
doi: 10.1093/ehjcvp/pvw047.
Authors
J Rick Turner
1
,
Erica Caveney
2
,
Barbara S Gillespie
3
,
Dilip R Karnad
4
,
Snehal Kothari
5
,
Alan Metz
6
,
Laurence H Keller
7
Affiliations
1
Cardiac Safety Services, QuintilesIMS, 4820 Emperor Blvd, Durham, NC 27703, USA.
2
Diabetes Center of Excellence, QuintilesIMS, 4820 Emperor Blvd, Durham, NC 27703, USA.
3
Office of the Chief Medical & Scientific Officer, 4820 Emperor Blvd, Durham, NC 27703, USA.
4
Research Team, Cardiac Safety Services, QuintilesIMS, 602 Western Express Highway, Andheri East, Mumbai 400 069, India.
5
Cardiac Safety Services, Cardiac Safety Center of Excellence, QuintilesIMS, 602 Western Express Highway, Andheri East, Mumbai 400 069, India.
6
Therapeutic and Specialty Centers of Excellence, QuintilesIMS, 4820 Emperor Blvd, Durham, NC 27703, USA.
7
Cardiovascular Center of Excellence, QuintilesIMS, 4820 Emperor Blvd, Durham, NC 27703, USA.
PMID:
28122792
DOI:
10.1093/ehjcvp/pvw047
No abstract available
Publication types
Letter
Comment
MeSH terms
Cardiovascular Diseases
Cardiovascular System*
Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents / adverse effects*
Treatment Outcome
Substances
Hypoglycemic Agents